Y-Mabs Therapeutics Inc (YMAB)

$4.82 +0.13 (2.77%)
Market Cap 212.07M
Revenue (ttm) 87.69M
Net Income (ttm) -29.67M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -33.84%
Debt to Equity Ratio 0.00
Volume 143,300
Avg Vol 387,882
Day's Range N/A - N/A
Shares Out 45.22M
Stochastic %K 53%
Beta 0.71
Analysts Strong Sell
Price Target $17.70

Latest News on YMAB

Y-mAbs Therapeutics: A Yawn From The Market Means Opportunity

Apr 11, 2025, 4:35 PM EDT - 10 days ago

Y-mAbs Therapeutics: A Yawn From The Market Means Opportunity

Y-mAbs Therapeutics, Inc. (YMAB) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 3:03 PM EST - 6 weeks ago

Y-mAbs Therapeutics, Inc. (YMAB) Q4 2024 Earnings Call Transcript

Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments

Mar 4, 2025, 6:35 AM EST - 6 weeks ago

Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments

Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications

Mar 3, 2025, 7:30 AM EST - 7 weeks ago

Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications

Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025

Feb 20, 2025, 4:05 PM EST - 2 months ago

Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025

Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference

Feb 6, 2025, 7:30 AM EST - 2 months ago

Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference

Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting

Jan 31, 2025, 7:35 AM EST - 2 months ago

Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting

Y-mAbs Therapeutics: Finding Direction Through The Murk Of Clinical Trials

Jan 24, 2025, 5:57 PM EST - 3 months ago

Y-mAbs Therapeutics: Finding Direction Through The Murk Of Clinical Trials

Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities

Jan 10, 2025, 9:26 AM EST - 3 months ago

Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities

Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit

Jan 10, 2025, 7:35 AM EST - 3 months ago

Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit

Y-mAbs Provides Strategic Business Update and 2025 Priorities

Jan 10, 2025, 7:05 AM EST - 3 months ago

Y-mAbs Provides Strategic Business Update and 2025 Priorities

Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 23, 2024, 7:30 AM EST - 4 months ago

Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting

Dec 7, 2024, 12:00 PM EST - 4 months ago

Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting

Y-mAbs to Participate at Citi's 2024 Global Healthcare Conference

Nov 27, 2024, 7:35 AM EST - 5 months ago

Y-mAbs to Participate at Citi's 2024 Global Healthcare Conference

Y-mAbs Therapeutics, Inc. (YMAB) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 1:58 PM EST - 5 months ago

Y-mAbs Therapeutics, Inc. (YMAB) Q3 2024 Earnings Call Transcript

Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments

Nov 8, 2024, 6:35 AM EST - 5 months ago

Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments

Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan

Nov 4, 2024, 7:35 AM EST - 6 months ago

Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan

Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast

Oct 25, 2024, 7:05 AM EDT - 6 months ago

Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast

Y-mAbs to Participate in Upcoming Investor Conferences in October

Oct 1, 2024, 7:05 AM EDT - 7 months ago

Y-mAbs to Participate in Upcoming Investor Conferences in October

Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research

Sep 6, 2024, 7:30 AM EDT - 8 months ago

Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research

Y-mAbs to Participate in Upcoming Investor Conferences in September

Sep 3, 2024, 8:32 AM EDT - 8 months ago

Y-mAbs to Participate in Upcoming Investor Conferences in September

Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)

Aug 12, 2024, 12:08 PM EDT - 9 months ago

Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)

Y-mAbs Therapeutics, Inc. (YMAB) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 11:20 AM EDT - 9 months ago

Y-mAbs Therapeutics, Inc. (YMAB) Q2 2024 Earnings Call Transcript

Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

Aug 12, 2024, 6:30 AM EDT - 9 months ago

Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

Y-mAbs to Participate in Upcoming Investor Conferences in August

Aug 7, 2024, 7:05 AM EDT - 9 months ago

Y-mAbs to Participate in Upcoming Investor Conferences in August

Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast

Aug 5, 2024, 4:05 PM EDT - 9 months ago

Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast

Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

Jul 1, 2024, 4:05 PM EDT - 10 months ago

Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting

Jun 7, 2024, 7:05 AM EDT - 11 months ago

Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting

Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer

Jun 5, 2024, 7:05 AM EDT - 11 months ago

Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer

Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting

Jun 1, 2024, 8:15 AM EDT - 11 months ago

Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting

Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting

Jun 1, 2024, 8:05 AM EDT - 11 months ago

Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting

Y-mAbs Therapeutics, Inc. (YMAB) Q1 2024 Earnings Call Transcript

May 8, 2024, 2:13 PM EDT - 1 year ago

Y-mAbs Therapeutics, Inc. (YMAB) Q1 2024 Earnings Call Transcript

Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024

Apr 26, 2024, 7:05 AM EDT - 1 year ago

Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024

Y-mAbs to Present at 2024 ASCO Annual Meeting

Apr 25, 2024, 4:05 PM EDT - 1 year ago

Y-mAbs to Present at 2024 ASCO Annual Meeting

Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer

Mar 14, 2024, 9:05 AM EDT - 1 year ago

Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer

Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors

Mar 4, 2024, 7:30 AM EST - 1 year ago

Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors

Y-mAbs Therapeutics, Inc. (YMAB) Q4 2023 Earnings Call Transcript

Mar 1, 2024, 10:33 AM EST - 1 year ago

Y-mAbs Therapeutics, Inc. (YMAB) Q4 2023 Earnings Call Transcript

Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

Feb 29, 2024, 4:05 PM EST - 1 year ago

Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024

Feb 16, 2024, 7:30 AM EST - 1 year ago

Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024

Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024, 4:05 PM EST - 1 year ago

Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index

Dec 13, 2023, 4:05 PM EST - 1 year ago

Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index

Y-mAbs Therapeutics, Inc. (YMAB) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 3:22 PM EST - 1 year ago

Y-mAbs Therapeutics, Inc. (YMAB) Q3 2023 Earnings Call Transcript

Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023

Oct 31, 2023, 7:05 AM EDT - 1 year ago

Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023

Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director

Oct 18, 2023, 4:05 PM EDT - 1 year ago

Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director

Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA

Oct 17, 2023, 4:05 PM EDT - 1 year ago

Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA

Y-mAbs Announces Publication in Cancers

Oct 16, 2023, 4:05 PM EDT - 1 year ago

Y-mAbs Announces Publication in Cancers

Y-mAbs: They Have Earnings, But Still Seek The Big Hit

Oct 11, 2023, 7:14 PM EDT - 1 year ago

Y-mAbs: They Have Earnings, But Still Seek The Big Hit

Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology

Sep 21, 2023, 4:05 PM EDT - 1 year ago

Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology